GLP-1 Medications: What Every Personal Trainer & Fitness Coach Needs to Know

A client messages you: “I started Ozempic last month. Didn’t want to mention it before.” The weight is dropping fast. But their progress photos tell a different story: they’re getting smaller, not leaner.

This is the GLP-1 coaching challenge. If you haven’t faced it yet, you will soon.

1. How common GLP-1 use already is among your potential client base (1 in 8 US adults)
2. The lean mass problem: up to 40% of weight lost on these drugs is muscle, not fat
3. Why resistance training and protein are non-negotiable for GLP-1 clients
4. Practical programming adjustments for energy, recovery, and GI side effects
5. The coaching conversations that matter most: stigma, expectations, and long-term planning

1 in 8 Adults Are Already on GLP-1 Medications

This isn’t a niche trend. GLP-1 receptor agonists are prescription medications that mimic a gut hormone to reduce appetite and slow gastric emptying, originally developed for type 2 diabetes and now widely prescribed for weight loss. The most common ones: semaglutide (brand names Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound).

According to a KFF Health Tracking Poll from November 2025, 1 in 8 US adults are currently taking a GLP-1 medication. That’s roughly 30 million people.

The clinical results explain the adoption. In the STEP 1 trial (1,961 participants), semaglutide produced an average weight loss of 14.9% over 68 weeks. Tirzepatide went further: the SURMOUNT-1 trial (2,539 participants) showed 20-22% weight loss at the highest dose.

These are not subtle changes. Your clients are losing 30, 40, 50+ pounds. Some of them are telling you about it. Others aren’t.

And the wave is going global. On March 20, 2026, semaglutide’s patent expired in India, and over 40 Indian pharmaceutical companies launched generic versions the next day. Monthly costs dropped from ₹11,000 ($119) to as low as ₹1,500 ($16). Analysts expect India’s GLP-1 market to double within a year. If you coach clients in India or other markets where generics are arriving, this isn’t coming. It’s here.

The Lean Mass Problem

The headline weight loss numbers are impressive. The body composition data is more complicated.

A DXA substudy of the STEP 1 trial found that approximately 40% of the weight lost on semaglutide was lean body mass. Not fat. Muscle, water bound to muscle, and other lean tissue. A systematic review of GLP-1 body composition studies calculated lean mass losses between 39-45% of total weight lost across multiple trials.

For context, in typical calorie-restricted weight loss without exercise, lean mass usually accounts for about 25% of weight lost. GLP-1 medications push that ratio higher, likely because the weight loss is faster and more substantial than most diet-only approaches. The SEMALEAN study (115 patients on semaglutide 2.4mg) added nuance: lean mass declined in the first 7 months but then stabilized, and muscle function actually improved. The picture isn’t all bad, but it depends entirely on what the client does alongside the medication.

At 15% total body weight loss, a client weighing 200 pounds loses about 30 pounds. If 40% of that is lean mass, that’s 12 pounds of muscle gone. For a client who’s been training with you, that’s months of progress reversed.

And here’s the part that should concern every fitness coach: when clients stop GLP-1 medications, the weight comes back. Wilding et al. (2022) tracked STEP 1 participants after they stopped semaglutide and found they regained roughly two-thirds of the weight within a year. But the muscle they lost doesn’t automatically return with the regained weight. What comes back is predominantly fat. Without intervention, the client ends up at a worse body composition than where they started.

Key GLP-1 Research for Fitness Coaches

Study	Participants	Key Finding
STEP 1 (Wilding, 2021)	1,961	14.9% weight loss; ~40% of loss was lean mass
SURMOUNT-1 (Jastreboff, 2022)	2,539	20-22% weight loss with tirzepatide
SEMALEAN (2025)	115	Lean mass declined then stabilized; muscle function improved
S-LiTE (Lundgren, 2021)	195	Exercise + GLP-1 preserved lean mass; doubled fat loss vs either alone
STEP 1 Extension (Wilding, 2022)	327	Two-thirds of weight regained within 1 year of stopping
India Generic Launch (2026)	40+ manufacturers	Semaglutide cost dropped from ₹11,000 to ₹1,500/month

Why GLP-1 Fitness Coaching Clients Need You More

There’s a perception in the fitness industry that GLP-1 medications make coaches obsolete. If a drug handles the hard part, what’s the point of a trainer?

The opposite is true.

GLP-1s solve the appetite problem. But they create a body composition problem that only structured resistance training and intentional nutrition can address. The medication gets the weight off. Your job is making sure it’s the right weight.

This is a significant professional opportunity. Major fitness organizations are already responding: ACE published guidance specifically on GLP-1s and lean mass for fitness professionals, and ACSM’s perspective on anti-obesity medications positions exercise professionals as “trusted partners” in the process. The CDC reports that 26.5% of adults with diagnosed diabetes are now on GLP-1 injectables. These clients are showing up at gyms, hiring coaches, and asking for help. The ones who find a coach who understands their situation will stay. The ones who don’t will lose muscle and quit.

You’re not replacing the doctor. You’re doing the part the doctor can’t: the programming, the habit-building, and the accountability that turns pharmaceutical weight loss into lasting body recomposition.

Programming for Fitness Coaching Clients on GLP-1s

The evidence is clear on what works.

Resistance training is non-negotiable

The S-LiTE trial (Lundgren et al., 2021, New England Journal of Medicine) randomized 195 adults to exercise alone, liraglutide (a GLP-1 medication) alone, the combination, or placebo after initial weight loss. The combination group maintained the most weight loss while preserving lean mass and continuing to lose fat. Exercise alone preserved muscle. The GLP-1 alone did not. Together, the body composition improvements were roughly double what either achieved alone.

A published case series of patients combining resistance training (3-5 days per week) with adequate protein and GLP-1 therapy found minimal lean mass loss. One patient lost just 8.7% of total weight as lean mass (compared to 40% in the STEP 1 trial without structured training). Two patients actually gained lean mass while losing fat. Small sample, but the direction is consistent with everything we know about resistance training during weight loss.

Practical adjustments

GLP-1 clients aren’t the same as your typical fat-loss clients. A few things to account for:

• Lower energy during dose titration. Every time the dose increases (typically monthly for the first 4-5 months), expect reduced energy and possible nausea for 1-2 weeks. Maintain intensity but be ready to reduce volume temporarily.
• GI timing matters. Nausea is the most common side effect, especially after meals. Many clients find training further from meals works better. Experiment with timing.
• Recovery may be impaired. Clients eating significantly less will recover slower. Monitor fatigue markers in their check-ins and adjust frequency or volume before they burn out.
• Prioritize compound movements. Squats, deadlifts, rows, presses. These recruit the most muscle mass per exercise and send the strongest muscle-preservation signal. This isn’t the time for an isolation-heavy split.
• Train 3-4x per week. Frequency matters more than marathon sessions. Three well-structured full-body or upper/lower sessions beat six unfocused ones when energy is limited.

The Protein Conversation in Fitness Coaching

Here’s the practical challenge: GLP-1 medications suppress appetite dramatically. Many clients struggle to eat enough, period. Getting them to eat enough protein is even harder.

The International Society of Sports Nutrition recommends 1.6-2.2 g of protein per kg of body weight per day for individuals doing resistance training. During a caloric deficit, the upper end of that range matters more. A review by Cava et al. (2017) in Advances in Nutrition specifically identifies adequate protein plus resistance training as the most effective combination for preserving lean mass during weight loss.

For a client weighing 80 kg (176 lbs), that means 128-176 grams of protein per day. When your client is barely eating 1,200 calories and feeling nauseous, that target feels impossible.

Strategies that work

• Protein first, every meal. When appetite is limited, every bite counts. Protein comes before vegetables, before carbs, before everything else.
• Liquid protein. Shakes, smoothies, protein-fortified drinks. When chewing feels like a chore (and GLP-1 nausea makes it one), liquids go down easier.
• Smaller, more frequent meals. Four to six small protein-rich meals may be more tolerable than three larger ones.
• Track it. GLP-1 clients often overestimate their protein intake because they’ve lost their internal hunger cues. Tracking, even for a few weeks, reveals the gap.

This is where coaching makes the difference. The medication suppresses appetite. You ensure the right food goes in despite the reduced appetite. Nobody’s doctor is providing meal-by-meal protein guidance. That’s your lane.

The Fitness Coaching Conversations That Matter

The technical side of GLP-1 coaching is straightforward: lift heavy, eat protein, track body composition. The human side is more nuanced.

Stigma and guilt

Many clients feel guilty about using medication for weight loss. “I should be able to do this on my own.” This is especially common with clients who’ve worked hard in the gym. They see medication as admitting defeat.

Your role here isn’t medical. It’s coaching. Reframe the narrative: the medication handles the biological appetite drive that was working against them. The training, the nutrition discipline, the consistency, that’s still all them. Nobody takes Ozempic and wakes up with a stronger squat. The work is still real.

Body composition expectations

Clients on GLP-1 medications often expect the scale drop to translate into looking leaner. When they see “soft” in the mirror instead, frustration follows. Set expectations early: the goal isn’t just weight loss. It’s losing fat while keeping (or building) muscle. That requires a different standard of progress, one that goes beyond scale weight.

When you track multiple metrics from the first check-in, measurements, photos, and strength numbers alongside weight, you can show the real story. “Your weight is down 12 pounds, but your squat went up 20 pounds and your waist is down an inch. You’re not just losing weight. You’re recomposing.”

The long-term plan

Weight regain after stopping GLP-1 medications is well-documented. Two-thirds of lost weight typically returns within a year. This isn’t a failure of willpower. It’s biology: the appetite suppression disappears when the drug stops.

This is where your onboarding and habit-building work matters most. The clients who sustain their results after stopping medication are the ones who built real habits during the medication phase: consistent training, protein-aware eating, regular check-ins. The medication gave them a window. Your coaching filled it with sustainable structure.

Frequently Asked Questions

Should fitness coaches refuse to train clients on GLP-1 medications?

No. GLP-1 clients need coaching more than typical clients, not less. The medication handles appetite, but preserving muscle requires structured resistance training and adequate protein. Refusing these clients means leaving them to lose muscle unsupervised.

Do I need a special certification to coach clients on Ozempic or Wegovy?

No special certification is required. You’re not prescribing or managing the medication. Your role is the same as always: programming, nutrition guidance, and accountability. But understanding how GLP-1s affect appetite, energy, and body composition will make you a better coach for these clients.

What if my GLP-1 client’s weight loss stalls?

Look beyond the scale. If weight has stalled but measurements are changing, they may be recomping: gaining muscle while losing fat. Track waist, hips, arms, and progress photos alongside weight. A plateau on the scale often hides real progress in body composition.

Is semaglutide available and affordable in India?

Yes. Semaglutide’s key patent expired in India on March 20, 2026, and over 40 pharmaceutical companies launched generic versions. Monthly costs dropped from around ₹11,000 to as low as ₹1,500. Fitness coaches in India should expect a significant increase in clients using these medications.

The Opportunity in Front of You

GLP-1 medications aren’t going away. The client base is growing. The medical system prescribes the drugs and monitors the bloodwork. But nobody in that system is programming the training, managing the protein intake, tracking the body composition, or having the conversation about what happens after the medication stops.

That’s your job. And these clients need it done well.

Ready to track what matters for every client? Try Assistant Coach free - body composition tracking, progress photo comparison, and AI-powered trend analysis included.

References

• Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384, 989-1002. PubMed
• Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387, 205-216. PubMed
• Wilding JPH, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. PubMed
• Ida S, et al. (2024). Systematic review of GLP-1 RA body composition effects. PubMed
• Lundgren JR, et al. (2021). Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine, 384(18), 1719-1730. PubMed
• Cava E, Yeat NC, Mittendorfer B. (2017). Preserving Healthy Muscle during Weight Loss. Advances in Nutrition, 8(3), 511-519. PubMed
• Jäger R, et al. (2017). International Society of Sports Nutrition Position Stand: Protein and Exercise. JISSN, 14, 20. PubMed
• KFF. (2025). 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug. kff.org
• SEMALEAN Study. (2025). Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity. PMC
• Tinsley GM, Nadolsky S. (2025). Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. PMC
• ACE Fitness. (2025). GLP-1s and Lean Mass: What the Research Shows. acefitness.org
• ACSM. (2025). A Perspective on Anti-Obesity Medications. acsm.org
• CDC/NCHS. (2025). Data Brief No. 537: GLP-1 Receptor Agonist Injectable Use Among Adults With Diagnosed Diabetes. cdc.gov
• Bloomberg. (2026). Ozempic Copies to Cost $14 in India as Generic GLP-1 Era Starts. bloomberg.com